Scopus
🔓 Açık Erişim
Nigella sativa L. and Its Active Compound Thymoquinone in the Clinical Management of Diabetes: A Systematic Review
International Journal of Molecular Sciences · Ekim 2022
Makale Bilgileri
DergiInternational Journal of Molecular Sciences
Yayın TarihiEkim 2022
Cilt / Sayfa23
Scopus ID2-s2.0-85140811214
Erişim🔓 Açık Erişim
Özet
Despite existing conventional hypoglycemic drugs to manage diabetes, their non-availability and cost in low-income countries coupled with the associated side effects remain a major concern. Consequently, exploring for alternative treatments to manage diabetes has been a continuous priority. Nigella sativa L. (NS) (Family: Ranunculaceae) is regarded as a valuable traditional remedy in diabetes management and extensively studied for its biological properties. This systematic review provides a comprehensive and critical analysis of clinical studies on the efficacy, safety, and mechanism of action of NS and its compound thymoquinone (TQ) in diabetes management. The main scientific databases which were scrutinised were Scopus, PubMed, Google Scholar, and Web of Science. Data search was conducted from inception to January 2022. A total of 17 clinical studies were obtained; 16 studies on Nigella sativa L. and 1 study on its compound TQ. N. sativa was found to be highly potent in terms of its hypoglycemic activity when compared to placebo based on improvement in parameters including fasting blood glucose (FBG), postprandial blood glucose (PPBG), Hemoglobin A1C (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), and homeostatic model assessment for assessment of beta-cell functionality (HOMA-β). The compound TQ in combination with a daily dose of metformin demonstrated a greater reduction in the levels of HbA1c and blood glucose compared to metformin alone. The bioavailability of TQ can be enhanced by using nanoparticulate drug delivery systems. Considering the findings of the clinical studies along with negligible adverse effects, NS has strong potential application in bioproduct development for the management of diabetes. Further investigations should explore the detailed mechanism of actions by which TQ exerts its therapeutic antidiabetic effects to provide more insights into its clinical use in the management of diabetes.
Yazarlar (5)
1
Mohamad Fawzi Mahomoodally
2
Muhammad Zakariyyah Aumeeruddy
3
Lesetja Legoabe
4
Domenico Montesano
ORCID: 0000-0002-8857-2091
5
Gokhan Zengin
ORCID: 0000-0001-6548-7823
Anahtar Kelimeler
clinical studies
diabetes
Nigella sativa
thymoquinone
Kurumlar
Duy Tan University
Da Nang Viet Nam
North-West University
Potchefstroom South Africa
Selçuk Üniversitesi
Selçuklu Turkey
Università degli Studi di Napoli Federico II
Naples Italy
University of Mauritius
Reduit Mauritius
Metrikler
12
Atıf
5
Yazar
4
Anahtar Kelime